news
Tessera’s gene editing offers hope for sickle cell patients
Find out how Tessera's latest advancements in gene editing bring promising solutions to treat sickle cell disease.
List view / Grid view
Drug Discovery Processes
news
Cancer Research Horizons collaborates with Diamond to accelerate drug discovery
Cancer Research Horizons has teamed up with Diamond Light Source to drive the discovery of new cancer treatments.
article
In vivo CAR T: Faster, cheaper, and more effective cancer care
Find out how in vivo cell therapies could transform cancer treatment by providing faster, more affordable, and accessible options for more patients.
article
Toxicology transformed: Why accuracy now leads the way
Regulatory changes are reshaping toxicology, with precision now at the forefront. We explore how accurate target analysis is transforming drug development, particularly for biotherapeutics.
article
AI paves the way for new immunotherapy targets
To fully unlock the potential of immunotherapy for cancer patients, we need better targets, not just better treatments. Hear from Michelle Teng, CEO of Etcembly, on how AI is decoding the immune repertoire and designing new therapies.
article
Nobel Prize celebrates AI’s role in protein structure innovation
The 2024 Nobel Prize in Chemistry honours AI's transformative impact on protein science, with breakthroughs set to reshape drug development.
news
E. coli alters ribosomes to survive antibiotic treatment
New study shows E. coli resists antibiotics by modifying its ribosome structure, blocking drug binding and enabling growth despite treatment.
article
Scientific workflow for hypothesis testing in drug discovery: Part 1 of 3
Explore the step-by-step scientific workflow behind drug discovery, from formulating hypotheses to analysing data, ensuring accurate and reliable results.
news
FDA greenlights AI-developed drug targeting solid tumors
Insilico Medicine’s AI-designed drug ISM5939 has received FDA IND clearance for treating solid tumours. By targeting ENPP1, it enhances anti-tumour immunity and is set to begin Phase I trials soon.
news
New CAR-T therapy shows promise in leukaemia treatment
Obecabtagene autoleucel (obe-cel) has demonstrated strong efficacy in treating relapsed B-cell leukemia, with high response rates and minimal side effects.
news
Metrion Biosciences appoints Lee Patterson as CEO
Metrion Biosciences is set to accelerate its global expansion and enhance its leadership in ion channel drug discovery services.
article
Unlocking a new molecular space in rapid drug discovery
So-called undruggable pharmaceutical targets could be tackled with intermediate sized drugs such as macrocycles, combining the advantages of small molecules and biologics. The preparation of very large libraries of chemically synthesised intermediate-sized molecules is now in reach with a new technology developed at ETH Zurich. In this article, Dr Michelle…
news
Overcoming the limitations of existing AI models
Researchers have developed a new AI tool which recognises that protein behaviour can vary by cell and by tissue type.
article
Part one: an introduction to data quality
In this four-part series, Dr Singh will discuss the challenges surrounding limited data quality, and some pragmatic solutions. In this first article, the key attributes that define data quality and its requirement for data scientists are elucidated.
webinar
Unprecedented fragment-based screening using Spectral Shift for GPCRs
2 August 2024 | By Eurofins Discovery
In this webinar, we will present how challenging recombinant protein such as GPCRs are produced and characterised and how biophysics participates in GPCRs hit finding and hit confirmation.